DanDrit Biotech A/S has signed a contract of collaboration with the University Hospital IRCCS “San Martino”.
The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evidence of disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.
“Over the last year,” noted Dr. Eric Leire, DanDrit’s Chief Executive Officer, “DanDrit has focused its efforts on developing MCV for colorectal cancer patients. We intend to continue our efforts to develop a vaccine that we hope can ameliorate the scourge of colorectal cancer.”
DanDrit Biotech A/S (“DanDrit Denmark”) is a biotechnology company focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. DanDrit Biotech A/S was founded in 2001 on the research of Professor Jesper Zeuthen at the Danish Cancer Society (Kraeftens Bekaempelse). It is the subsidiary of DanDrit Biotech USA, Inc.